MarketVIEW - Staphylococcus aureus vaccines

  • April 2012
  • -
  • VacZine Analytics Group Of Assay Advantage Ltd

Gram-positive Staphylococcus aureus is an opportunistic pathogen and a major cause of patient morbidity and mortality, especially in "at risk" populations. The organism can cause a wide range of infections ranging from mild skin infections to life-threatening bloodstream infections and pneumonia.

Prophylatic vaccines could prevent S.aureus infections and become cost effective in achieving savings from expensive infection control interventions e.g. MRSA screening on admission. Although all major companies have now announced S.aureus vaccine programs, Pfizer (SA4Ag) are the most advanced now the Merck & Co (Intercell AG) candidate, V710 has been terminated.

This MarketVIEW product gives a comprehensive vaccine value ($USD/volume (000s) forecast for all products within target nosocomial populations until 2030. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing targetting/competitive and pricing scenarios. This product is an essential component of any commercial opportunistic assessment focused on nosocomial vaccines.


Table Of Contents

Contents - Summary presentation (MS PowerPoint based)

Author’s note
Executive Summary
Commercial model - key outputs
Total global available market ($000s all scenarios), pricing level 1
Total global available market ($000s all scenarios), pricing level 2
Total global available market ($000s all scenarios), pricing level 3
Total predicted demand (doses 000s all scenarios)
Total available volume per vaccine segment, US - 2025
Model forecast comparisons: March 2010 v current (April 2012) - volume/value
Model forecast comparisons: March 2010 v current (April 2012) - per segment
Company revenue summary
Modelling commercial potential
The role of S.aureus vaccine
Characteristics of the ideal S.aureus vaccine
S.aureus vaccine: target product profile (minimum)
S.aureus vaccine: target product profile (ideal)
Target populations: vaccination strategies
Vaccine target populations: overview
Vaccine target populations: scenario definition
Markets included in model
Commercial model assumptions: general
Commercial model assumptions: short-term risk
Commercial model assumptions: chronic risk
Model forecast assumptions: comparing March 2010 with current (April 2012)
Notes on Pricing
S.aureus vaccines: RandD pipeline
Competitor landscape overview
S.aureus vaccine: estimated launch dates
Pfizer: SA4Ag - background
Pfizer: SA4Ag - Phase I data
GSK: GSK2392103A/Nabi
Other vaccine candidates
Merck and Co/Intercell AG - V710
Staphylococcus aureus: update on infection control
Situation overview: MRSA infection control
US situation
Review of latest epidemiology
Acute care hospitals: US
Acute care hospitals: pan-European
Acute care hospitals: UK
Acute care hospitals: Germany
Acute care hospitals: France
Europe: methicillin-resistance disease trends
MRSA: colonization rates
Backup material: methodology
Methodology: general comments - CABG, ESRD and LTCFs
Methodology: general comments - ICU/elective
Methodology: general comments - diabetics
About VacZine Analytics

PAGES: 80 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents - Vaccine demand model (MS Excel-based)

Title sheet
TOTAL CHARTS - forecast to 2030
CHARTS VALUE - pricing level 1
CHARTS VALUE - pricing level 2
CHARTS VALUE - pricing level 3
VALUE SUMMARY - pricing level 1
VALUE SUMMARY - pricing level 2
VALUE SUMMARY - pricing level 3
Competitor summary (Base scenario)
US (all scenarios LO/BASE/HIGH)
EU - other
Country target populations - forecast to 2030
Source material
Hospital admissions
Elective admissions
US segments
Back page
About VacZine Analytics


View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

DNA Vaccines: Technologies and Global Markets

DNA Vaccines: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • July 2014
  • by BCC Research

This BCC Research study determines the specific applications and global market demand for DNA vaccine products over a five-year period from 2014 to 2019. High growth and market potential segments of the ...

Detailed I/E report of Carbendazim export analysis

Detailed I/E report of Carbendazim export analysis

  • $ 5 400
  • Industry report
  • July 2014
  • by CCM International Limited

Carbendazim export analysis will help clients indentify export situation of technical and formulations with exclusive research methods, to offer not only the target products' export volume, price, time, ...

Global Pediatric Drugs and Vaccines Market

Global Pediatric Drugs and Vaccines Market

  • $ 4 950
  • Industry report
  • September 2014
  • by Global Industry Analysts

This report analyzes the worldwide markets for Pediatric Drugs and Vaccines in US$ Million by the following Therapeutic Class: Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective ...

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.